156 related articles for article (PubMed ID: 36555913)
1. Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience.
Remy C; Caron B; Gouynou C; Haghnejad V; Jeanbert E; Netter P; Danese S; Peyrin-Biroulet L
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555913
[TBL] [Abstract][Full Text] [Related]
2. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study.
Ribaldone DG; Parisio L; Variola A; Bossa F; Castiglione F; Marzo M; Piazza N; Aratari A; Savarino EV; Bodini G; Mastronardi M; Micheli F; Mazzuoli S; Ascolani M; Viganò C; Cappello M; Bezzio C; Ciccocioppo R; Scardino G; Sarli E; Pugliese D; Scaldaferri F; Napolitano D; Todeschini A; Geccherle A; Colaci N; Guerra M; Annese M; Testa A; Caiazzo A; Conforti FS; Festa S; Lorenzon G; Marra A; Magiotta A; Baccini F; Amato A; Poshnjari A; Vernero M; Caprioli F; Caviglia GP;
Dig Liver Dis; 2024 Jan; 56(1):77-82. PubMed ID: 37474412
[TBL] [Abstract][Full Text] [Related]
3. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.
Fierens L; Liefferinckx C; Hoefkens E; Lobatòn T; Dreesen E; Sabino J; Ferrante M
J Crohns Colitis; 2022 Aug; 16(7):1059-1069. PubMed ID: 35078228
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.
Wiken TH; Høivik ML; Anisdahl K; Buer L; Warren DJ; Bolstad N; Hagen M; Moum BA; Medhus AW
Crohns Colitis 360; 2024 Jan; 6(1):otae013. PubMed ID: 38544907
[TBL] [Abstract][Full Text] [Related]
5. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease.
Haar GS; Vasudevan A; Curtain CM; van Langenberg DR
Res Social Adm Pharm; 2021 Aug; 17(8):1420-1425. PubMed ID: 33129684
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
[TBL] [Abstract][Full Text] [Related]
7. Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.
Alten R; An Y; Kim DH; Yoon S; Peyrin-Biroulet L
Clin Drug Investig; 2022 Jun; 42(6):477-489. PubMed ID: 35657560
[TBL] [Abstract][Full Text] [Related]
8. Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations.
Burdge G; Hardman A; Carbery I; Broglio G; Greer D; Selinger CP
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233537
[TBL] [Abstract][Full Text] [Related]
9. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
Bergqvist V; Holmgren J; Klintman D; Marsal J
Aliment Pharmacol Ther; 2022 Jun; 55(11):1389-1401. PubMed ID: 35470449
[TBL] [Abstract][Full Text] [Related]
10. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
Hilley P; Wong D; Ma R; Peterson A; De Cruz P
Intern Med J; 2024 Jun; 54(6):970-979. PubMed ID: 38214034
[TBL] [Abstract][Full Text] [Related]
11. Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience.
Oršić Frič V; Borzan V; Šahinović I; Borzan A; Kurbel S
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259387
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease.
Amor Costa C; Suárez Ferrer C; García Ramírez L; Martín-Arranz E; Poza Cordón J; Rueda García JL; Sánchez Azofra M; González Diaz I; Amiama Roig C; Martín-Arranz MD
Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723766
[TBL] [Abstract][Full Text] [Related]
13. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
Null K; Kumar V; Lissoos T; Luo M
J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series.
Anjie SI; Gecse KB; Ponsioen CY; Löwenberg M; D'Haens GR
Therap Adv Gastroenterol; 2024; 17():17562848241228080. PubMed ID: 38406796
[TBL] [Abstract][Full Text] [Related]
15. Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.
Liefferinckx C; Verstockt B; Gils A; Tops S; Van Moerkercke W; Vermeire S; Franchimont D
United European Gastroenterol J; 2019 Jul; 7(6):750-758. PubMed ID: 31316779
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
18. Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
Fernandes SR; Rodrigues IC; Serrazina J; Botto IA; Bernardo S; Gonçalves AR; Valente A; Moura Santos P; Correia LA; Marinho RT
Scand J Gastroenterol; 2022 Oct; 57(10):1202-1208. PubMed ID: 35599574
[TBL] [Abstract][Full Text] [Related]
19. High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients.
Sutter M; Hruz P; Niess JH
Inflamm Intest Dis; 2021 Sep; 6(3):165-174. PubMed ID: 34722646
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
